About Us
Developing Treatments for CD127 Expressing Cancers
With an initial focus on hematological malignancies, Allterum Therapeutics is developing 4A10, an anti-CD127 monoclonal antibody for treating acute lymphoblastic leukemia (ALL), B-cell malignancies, and lymphomas with CD127 over-expression. Allterum is also exploring relapsed/refractory solid tumors with CD127 over-expression. The 4A10 antibody was developed at the National Cancer Institutes (NCI) and licensed exclusively to Fannin. Allterum was incubated and launched out of Fannin, an early-stage life science commercialization group, which has assigned its executed license. The company is working with national leaders in cancer at Baylor College of Medicine, Texas Children’s Hospital, the Children’s Oncology Group (COG), the NCI, the Leukemia and Lymphoma Society, and the University of Texas MD Anderson Cancer Center to develop the technology.
Allterum is a Fannin company.
Allterum Therapeutics, Inc. was founded by Fannin in 2018 in Houston, TX. Fannin is Houston's most active early-stage life sciences development group with the primary focus being on development of early stage assets, in partnership with our academic collaborators. The studio’s assets include internally developed assets like Brevitest and in-licensed assets from academic institutions including local Houstonian institutions such as MD Anderson Cancer Center, Baylor College of Medicine, Rice University, Houston Methodist, Texas A&M, Texas Children’s, University of Texas, and University of Houston.
Our Mission
We advance precision medicine through uncompromising science and meaningful innovation — developing oncology and inflammation therapies that deliver extraordinary accuracy, transform treatment pathways, and change patient lives…because #PatientsCantWait.
Continuing the Fight in Hematologic Malignancies
Today, the five-year survival rate for children diagnosed with acute lymphoblastic leukemia (ALL) is over 90% – a result of a lengthy frontline chemotherapy regimen. Unfortunately, not all patients respond so favorably. The patient's subtype of acute lymphoblastic leukemia determines whether or not they have effective standard treatment options available after frontline therapy. Moreover, although ALL is primarily a pediatric disease, with fewer than 20% of new diagnoses in the United States occurring in adults, the prognosis in adults can be even worse than in children. Patients with relapsed/refractory T-Cell ALL have a critical unmet medical need with poor outcomes and only one new drug (nelarabine) approved in the last fifteen years. Allterum is seeking to change this by developing a targeted therapy for the treatment of patients with relapsed or refractory T-cell ALL and certain B-cell hematologic malignancies.
Exploring Other CD127 Expressing Cancers
Ongoing pre-clinical studies focused on lymphomas and solid tumors will extend Allterum’s clinical program to other metastatic disease with CD127 over-expression where the overall survival is usually less than 20%.
~5000
new cases of pediatric ALL each year
~1000
new cases of T-cell ALL each year
~160
new cases of relapsed/refactory T-cell ALL each year
~80000
cases of metastatic diseases with CD127 over-expression each year